FDA to hold public meetings on DTC

Share this article:
The FDA will be seeking comment on the presentation of risk information, the use of certain advertising strategies, comparative DTC promotion and other topics during a public meeting scheduled for Nov. 1 and Nov. 2 in Washington, D.C.
Notice of the meeting was posted in the Federal Register on Sept. 13.
"FDA is interested in hearing whether the indication of a drug or device can be effectively communicated to a lay audience under the confines of DTC promotion," the public notice read. "FDA is also specifically interested in whether paying greater attention to the educational component of an advertisement would help consumers better understand the role drug and device therapy may play in treating the disease."
The agency is also expected to seek comment on whether free samples, coupons and money-back guarantees are promoting undue influence over consumers.
Share this article:

Email Newsletters

More in News

Astellas, DOJ settle for $7.3M

Astellas, DOJ settle for $7.3M

Astellas has settled a False Claims case with the Department of Justice over the 2010-2013 marketing of an antifungal medication. Astellas denies the allegations.

Boehringer drug lands US, EU orphan tag

Boehringer drug lands US, EU orphan tag

The experimental Breakthrough Therapy treatment is for acute myeloid leukemia.

Omnio app moves to smartphones

Omnio app moves to smartphones

Physicians Interactive is introducing the third wave of its Omnio app, making the tablet-only tool available for iPhones and Android phones.